Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 CAR NK cells therapy - Shanghai Simnova Biotechnology

Next Previous
Drug Profile

Anti-CD19 CAR NK cells therapy - Shanghai Simnova Biotechnology

Alternative Names: Anti-CD19 CAR-Engineered NK cells therapy - Shanghai Simnova Biotechnology; Anti-cd19 chimeric antigen receptor natural killer cell therapy- Shanghai Simnova Biotechnology; CAR-NK-CD19 Cells - Shanghai Simnova Biotechnology; F-01; SNC-103

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Simnova Biotechnology
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders; Non-Hodgkin's lymphoma
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral)
  • 15 Jun 2024 Shanghai Simnova Biotechnology plans a phase I trial for Systemic lupus erythematosus in China (Parenteral), in June 2024 (NCT06468683)
  • 09 Jan 2024 Phase-I clinical trials in Autoimmune disorders in China (Parenteral) (NCT06208280)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top